QuantaLife has developed the third generation of PCR technology that quantifies DNA molecules by Droplet DigitalTM PCR. Droplet Digital PCR reduces the cost of quantitative PCR, while providing an absolute measure of target molecules with unrivalled quantitative resolution and sensitivity.
Applications include copy number variation (CNV), mutation detection, and gene expression analysis. This technology can accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
In October 2011, Bio-Rad Laboratories Inc. purchased QuantaLife Inc. for $162 million in cash plus potential future milestone payments.
Life Science Tools & Diagnostics
Investment’s Exit Date